Skip to main content
Erschienen in: Drugs 12/2011

01.08.2011 | Leading Article

Edoxaban

A New Oral Direct Factor Xa Inhibitor

verfasst von: Prof. A. John Camm, Henri Bounameaux

Erschienen in: Drugs | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Abstract

Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolic events (VTE).
Factor Xa is an attractive target for anticoagulant treatment, as it is the primary and rate-limiting source of amplification in the coagulation cascade. Edoxaban is a competitive inhibitor of factor Xa and has >10 000-fold greater selectivity for factor Xa relative to thrombin. In phase I clinical trials, the anticoagulant effects of edoxaban included dose-dependent increases in activated partial thromboplastin time and prothrombin time following single edoxaban doses of 10–150 mg and after multiple ascending doses (60 mg twice daily, 90 mg daily and 120 mg daily). The anticoagulant effects of edoxaban were rapid in onset (time to peak plasma concentration 1–2 hours) and sustained for up to 24 hours. Prolongation of bleeding time in 8% of subjects was >9.5 minutes (none of which appeared to be clinically significant) 2 hours after initial dosing, and was independent of edoxaban dose, formulation or dietary state. In general, plasma edoxaban concentrations were linearly correlated with coagulation parameters. Phase II clinical trials in patients with AF and VTE suggest that the edoxaban 30 mg once-daily and 60 mg once-daily regimens had a similar or better safety profile compared with dose-adjusted warfarin (international normalized ratio 2.0-3.0) in terms of bleeding events, and that edoxaban was not associated with hepatotoxicity. In addition, edoxaban was associated with statistically significant dose-dependent reductions in VTE after orthopaedic surgery compared with placebo or dalteparin sodium. Further clinical investigation of the efficacy and safety of once-daily edoxaban is being conducted in phase III clinical trials in comparison with warfarin in patients with AF in the phase III ENGAGE AF-TIMI 48 trial (NCT00781391), and in comparison with low-molecular weight heparin/warfarin in the prevention of recurrent VTE in patients with symptomatic deep vein thrombosis and/or pulmonary embolism in the HOKUSAI VTE trial (NCT00986154).
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation — executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006 Aug 15; 48(4): 854–906PubMedCrossRef Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation — executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006 Aug 15; 48(4): 854–906PubMedCrossRef
2.
Zurück zum Zitat Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010 Oct; 31(19): 2369–429PubMedCrossRef Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010 Oct; 31(19): 2369–429PubMedCrossRef
3.
Zurück zum Zitat Camm AJ, Kirchhof P, Lip GY, et al. on behalf of the European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010 Oct; 12(10): 1360–420PubMed Camm AJ, Kirchhof P, Lip GY, et al. on behalf of the European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010 Oct; 12(10): 1360–420PubMed
4.
Zurück zum Zitat Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 Jun; 133 (6 Suppl.): 381S–453SPubMedCrossRef Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 Jun; 133 (6 Suppl.): 381S–453SPubMedCrossRef
5.
Zurück zum Zitat Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 Jun; 133 (6 Suppl.): 454S–545SPubMedCrossRef Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 Jun; 133 (6 Suppl.): 454S–545SPubMedCrossRef
6.
Zurück zum Zitat Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 204S–33SPubMedCrossRef Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 204S–33SPubMedCrossRef
7.
Zurück zum Zitat Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008 Sep; 29(18): 2276–315PubMedCrossRef Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008 Sep; 29(18): 2276–315PubMedCrossRef
8.
Zurück zum Zitat Stone WM, Tonnessen BH, Money SR. The new anticoagulants. Perspect Vasc Surg Endovasc Ther 2007 Sep; 19(3): 332–5PubMedCrossRef Stone WM, Tonnessen BH, Money SR. The new anticoagulants. Perspect Vasc Surg Endovasc Ther 2007 Sep; 19(3): 332–5PubMedCrossRef
9.
Zurück zum Zitat Donnan GA, Dewey HM, Chambers BR. Warfarin for atrial fibrillation: the end of an era? Lancet Neurol 2004 May; 3(5): 305–8PubMedCrossRef Donnan GA, Dewey HM, Chambers BR. Warfarin for atrial fibrillation: the end of an era? Lancet Neurol 2004 May; 3(5): 305–8PubMedCrossRef
10.
Zurück zum Zitat Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007 May 29; 115(21): 2689–96PubMedCrossRef Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007 May 29; 115(21): 2689–96PubMedCrossRef
11.
Zurück zum Zitat Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008 Nov 11; 118(20): 2029–37PubMedCrossRef Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008 Nov 11; 118(20): 2029–37PubMedCrossRef
12.
Zurück zum Zitat Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006 Apr; 37(4): 1070–4PubMedCrossRef Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006 Apr; 37(4): 1070–4PubMedCrossRef
13.
Zurück zum Zitat Ali S, Hong M, Antezano ES, et al. Evaluation and management of atrial fibrillation. Cardiovasc Hematol Disord Drug Targets 2006 Dec; 6(4): 233–44PubMedCrossRef Ali S, Hong M, Antezano ES, et al. Evaluation and management of atrial fibrillation. Cardiovasc Hematol Disord Drug Targets 2006 Dec; 6(4): 233–44PubMedCrossRef
14.
Zurück zum Zitat Savelieva I, Camm J. Update on atrial fibrillation: part I. Clin Cardiol 2008 Feb; 31(2): 55–62PubMedCrossRef Savelieva I, Camm J. Update on atrial fibrillation: part I. Clin Cardiol 2008 Feb; 31(2): 55–62PubMedCrossRef
15.
Zurück zum Zitat Huisman MV, Bounameaux H. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention. Semin Vasc Med 2005 Aug; 5(3): 276–84PubMedCrossRef Huisman MV, Bounameaux H. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention. Semin Vasc Med 2005 Aug; 5(3): 276–84PubMedCrossRef
16.
Zurück zum Zitat Bajpai A, Savelieva I, Camm AJ. Treatment of atrial fibrillation. Br Med Bull 2008 Dec 1; 88(1): 75–94PubMedCrossRef Bajpai A, Savelieva I, Camm AJ. Treatment of atrial fibrillation. Br Med Bull 2008 Dec 1; 88(1): 75–94PubMedCrossRef
17.
Zurück zum Zitat Ederhy S, Meuleman C, Hammoudi N, et al. Preventing cerebrovascular accidents during atrial fibrillation. Presse Med 2005 Oct 22; 34(18): 1315–24PubMedCrossRef Ederhy S, Meuleman C, Hammoudi N, et al. Preventing cerebrovascular accidents during atrial fibrillation. Presse Med 2005 Oct 22; 34(18): 1315–24PubMedCrossRef
18.
Zurück zum Zitat Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007 Jun; 27(6): 1238–47PubMedCrossRef Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007 Jun; 27(6): 1238–47PubMedCrossRef
19.
Zurück zum Zitat Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010 Jul 5; 104(1): 49–60PubMedCrossRef Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010 Jul 5; 104(1): 49–60PubMedCrossRef
20.
Zurück zum Zitat Mavrakanas T, Bounameaux H. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther 2011 Apr; 130(1): 46–58PubMedCrossRef Mavrakanas T, Bounameaux H. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther 2011 Apr; 130(1): 46–58PubMedCrossRef
21.
Zurück zum Zitat Piccini JP, Lopes RD, Mahaffey KW. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Curr Opin Cardiol 2010 Jul; 25(4): 312–20PubMedCrossRef Piccini JP, Lopes RD, Mahaffey KW. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Curr Opin Cardiol 2010 Jul; 25(4): 312–20PubMedCrossRef
22.
Zurück zum Zitat Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008 Jan; 29(2): 155–65PubMedCrossRef Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008 Jan; 29(2): 155–65PubMedCrossRef
23.
Zurück zum Zitat Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmaco-dynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 2009; 48(1): 1–22PubMedCrossRef Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmaco-dynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 2009; 48(1): 1–22PubMedCrossRef
24.
Zurück zum Zitat Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010 Aug 5; 104(3): 633–41PubMedCrossRef Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010 Aug 5; 104(3): 633–41PubMedCrossRef
25.
Zurück zum Zitat Fuji T, Fujita S, Tachibana S, et al. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 2010 Nov; 8(11): 2458–68PubMedCrossRef Fuji T, Fujita S, Tachibana S, et al. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 2010 Nov; 8(11): 2458–68PubMedCrossRef
26.
Zurück zum Zitat Hylek E. DU-176b, an oral, direct Factor Xa antagonist. Curr Opin Investig Drugs 2007 Sep; 8(9): 778–83PubMed Hylek E. DU-176b, an oral, direct Factor Xa antagonist. Curr Opin Investig Drugs 2007 Sep; 8(9): 778–83PubMed
27.
Zurück zum Zitat Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007 Dec; 5(12): 2368–75PubMedCrossRef Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007 Dec; 5(12): 2368–75PubMedCrossRef
28.
Zurück zum Zitat Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010 Mar 6; 375(9717): 807–15PubMedCrossRef Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010 Mar 6; 375(9717): 807–15PubMedCrossRef
29.
Zurück zum Zitat Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009 Aug 6; 361(6): 594–604PubMedCrossRef Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009 Aug 6; 361(6): 594–604PubMedCrossRef
30.
Zurück zum Zitat Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006 Nov 28; 114(22): 2374–81PubMedCrossRef Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006 Nov 28; 114(22): 2374–81PubMedCrossRef
31.
Zurück zum Zitat Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement: a phase II dose-ranging study. J Thromb Haemost 2005 Nov; 3(11): 2479–86PubMedCrossRef Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement: a phase II dose-ranging study. J Thromb Haemost 2005 Nov; 3(11): 2479–86PubMedCrossRef
32.
Zurück zum Zitat ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010 Mar; 159(3): 340–7 e1CrossRef ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010 Mar; 159(3): 340–7 e1CrossRef
33.
Zurück zum Zitat Hacke W, Patel MR, Becker RC, et al. Baseline characteristics of the ROCKET AF study: comparison with recent atrial fibrillation studies [abstract OAID 5]. Poster presented at the 19th European Stroke Conference (ESC); 2010 May 25–8; Barcelona, Spain Hacke W, Patel MR, Becker RC, et al. Baseline characteristics of the ROCKET AF study: comparison with recent atrial fibrillation studies [abstract OAID 5]. Poster presented at the 19th European Stroke Conference (ESC); 2010 May 25–8; Barcelona, Spain
34.
Zurück zum Zitat Patel MR. Stroke prevention using the oral direct factor Xa Inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF) [abstract 21839]. Circulation 2010; 122(21): 2215–26CrossRef Patel MR. Stroke prevention using the oral direct factor Xa Inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF) [abstract 21839]. Circulation 2010; 122(21): 2215–26CrossRef
35.
Zurück zum Zitat Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 Sep 17; 361(12): 1139–51PubMedCrossRef Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 Sep 17; 361(12): 1139–51PubMedCrossRef
36.
Zurück zum Zitat Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007 Nov 1; 100(9): 1419–26PubMedCrossRef Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007 Nov 1; 100(9): 1419–26PubMedCrossRef
37.
Zurück zum Zitat Furugohri T, Isobe K, Honda Y, et al. Pharmacological characterization, antithrombotic and bleeding effects of DU-176b, a novel, potent and orally active direct inhibitor of factor Xa: a wider safety margin of antithrombotic and bleeding effects compared to heparin, LMWH and warfarin [abstract]. J Thromb Haemost 2005; 3 Suppl. 1: P1 110 Furugohri T, Isobe K, Honda Y, et al. Pharmacological characterization, antithrombotic and bleeding effects of DU-176b, a novel, potent and orally active direct inhibitor of factor Xa: a wider safety margin of antithrombotic and bleeding effects compared to heparin, LMWH and warfarin [abstract]. J Thromb Haemost 2005; 3 Suppl. 1: P1 110
38.
Zurück zum Zitat Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010 Jul; 50(7): 743–53PubMedCrossRef Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010 Jul; 50(7): 743–53PubMedCrossRef
39.
Zurück zum Zitat Zafar MU, Vorchheimer DA, Gaztanaga J, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007 Oct; 98(4): 883–8PubMed Zafar MU, Vorchheimer DA, Gaztanaga J, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007 Oct; 98(4): 883–8PubMed
40.
Zurück zum Zitat Mendell J, Tachibana M, Shi M, et al. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa Inhibitor, in healthy volunteers. J Clin Pharmacol 2011 May; 51(5): 687–94PubMedCrossRef Mendell J, Tachibana M, Shi M, et al. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa Inhibitor, in healthy volunteers. J Clin Pharmacol 2011 May; 51(5): 687–94PubMedCrossRef
41.
Zurück zum Zitat Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006 May; 46(5): 549–58PubMedCrossRef Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006 May; 46(5): 549–58PubMedCrossRef
42.
Zurück zum Zitat Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005 May; 45(5): 555–63PubMedCrossRef Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005 May; 45(5): 555–63PubMedCrossRef
43.
Zurück zum Zitat Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI48). Am Heart J 2010 Oct; 160(4): 635–41 e2PubMedCrossRef Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI48). Am Heart J 2010 Oct; 160(4): 635–41 e2PubMedCrossRef
44.
Zurück zum Zitat European Medicines Agency. Xarelto (rivaroxaban): summary of product characteristics. Bayer Schering Pharma; 2009 May European Medicines Agency. Xarelto (rivaroxaban): summary of product characteristics. Bayer Schering Pharma; 2009 May
45.
Zurück zum Zitat Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010 Jun; 64(7): 956–67PubMedCrossRef Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010 Jun; 64(7): 956–67PubMedCrossRef
46.
Zurück zum Zitat Pradaxa (dabigatran etexilate mesylate): US prescribing information. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals Inc, 2011 Ma Pradaxa (dabigatran etexilate mesylate): US prescribing information. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals Inc, 2011 Ma
47.
Zurück zum Zitat Masumoto H, Yoshigae Y, Watanabe K, et al. In vitro metabolism of edoxaban and the enzymes involved in the oxidative metabolism of edoxaban [abstract]. AAPS J 2010; 12(S2): W4308 Masumoto H, Yoshigae Y, Watanabe K, et al. In vitro metabolism of edoxaban and the enzymes involved in the oxidative metabolism of edoxaban [abstract]. AAPS J 2010; 12(S2): W4308
48.
Zurück zum Zitat Daiichi Sankyo Inc. Global study to assess the safety and effectiveness of DU-176b vs standard practice of dosing with warfarin in patients with atrial fibrillation (EngageAFTIMI48) [ClinicalTrials.gov identifier NCT00781391]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 13] Daiichi Sankyo Inc. Global study to assess the safety and effectiveness of DU-176b vs standard practice of dosing with warfarin in patients with atrial fibrillation (EngageAFTIMI48) [ClinicalTrials.gov identifier NCT00781391]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2011 Jul 13]
49.
Zurück zum Zitat Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008 Sep; 6(9): 1542–9PubMed Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008 Sep; 6(9): 1542–9PubMed
50.
Zurück zum Zitat Morishima Y, Fukuda T, Honda Y, et al. Activated prothrombin complex concentrate, recombinant factor VIII and factor IX reverse prolonged clotting time induced by DU-176B, a direct factor XA inhibitor, in human plasma [abstract]. J Thromb Haemost 2007; 5 Suppl. 2: P–T–639 Morishima Y, Fukuda T, Honda Y, et al. Activated prothrombin complex concentrate, recombinant factor VIII and factor IX reverse prolonged clotting time induced by DU-176B, a direct factor XA inhibitor, in human plasma [abstract]. J Thromb Haemost 2007; 5 Suppl. 2: P–T–639
51.
Zurück zum Zitat Morishima Y, Hornick P, Matsumoto C, et al. Recombinant factor VIIa reverses prolonged bleeding time induced by a high dose of DU-176b, a novel direct factor Xa inhibitor, in rats [abstract]. J Thromb Haemost 2005; 3 Suppl. 1 P0512 Morishima Y, Hornick P, Matsumoto C, et al. Recombinant factor VIIa reverses prolonged bleeding time induced by a high dose of DU-176b, a novel direct factor Xa inhibitor, in rats [abstract]. J Thromb Haemost 2005; 3 Suppl. 1 P0512
52.
Zurück zum Zitat Morishima Y, Honda Y, Matsumoto C, et al. Thrombin generation is a possible marker for a haemostatic action of recombinant factor VIIa to shorten prolonged bleeding time provoked by a high dose of a direct factor Xa inhibitor in rats [abstract]. Eur Heart J 2008; 29 Suppl.: 331 Morishima Y, Honda Y, Matsumoto C, et al. Thrombin generation is a possible marker for a haemostatic action of recombinant factor VIIa to shorten prolonged bleeding time provoked by a high dose of a direct factor Xa inhibitor in rats [abstract]. Eur Heart J 2008; 29 Suppl.: 331
53.
Zurück zum Zitat Samama M, Mendell J, Guinet C, et al. Comparison of the effect of edoxaban and fondaparinux on the inhibition of thrombin generation (in-vitro study) [abstract]. Pathophysiol Haemost Thromb 2010; 37 Suppl. 1: P407 Samama M, Mendell J, Guinet C, et al. Comparison of the effect of edoxaban and fondaparinux on the inhibition of thrombin generation (in-vitro study) [abstract]. Pathophysiol Haemost Thromb 2010; 37 Suppl. 1: P407
54.
Zurück zum Zitat Samama M, Woltz M, Ogata K, et al. Effect of edoxaban (DU-176b) on thrombin generation and platelet activation in shed and venous blood with fondaparinux as active comparator [abstract]. ESC Congress 2009: Annual Congress of the European Society of Cardiology; 2009 Aug 29–Sep 2; Barcelona, Spain, P2105 Samama M, Woltz M, Ogata K, et al. Effect of edoxaban (DU-176b) on thrombin generation and platelet activation in shed and venous blood with fondaparinux as active comparator [abstract]. ESC Congress 2009: Annual Congress of the European Society of Cardiology; 2009 Aug 29–Sep 2; Barcelona, Spain, P2105
55.
Zurück zum Zitat Morishima Y, Shirasaki Y, Kito F, et al. A wide safety margin of a factor Xa inhibitor, DU-176b, between anti-thrombotic effect and exacerbation of intracerebral hemorrhage in rats: comparison with a thrombin inhibitor [abstract]. Circulation 2006; 114(II): 104 Morishima Y, Shirasaki Y, Kito F, et al. A wide safety margin of a factor Xa inhibitor, DU-176b, between anti-thrombotic effect and exacerbation of intracerebral hemorrhage in rats: comparison with a thrombin inhibitor [abstract]. Circulation 2006; 114(II): 104
56.
Zurück zum Zitat Mendell J, Basavapathruni R, Swearingen D, et al. A thorough electrocardiogram study of edoxaban, a novel factor Xa inhibitor. J Clin Pharmacol Epub 2011 Jan 5 Mendell J, Basavapathruni R, Swearingen D, et al. A thorough electrocardiogram study of edoxaban, a novel factor Xa inhibitor. J Clin Pharmacol Epub 2011 Jan 5
57.
Zurück zum Zitat Raskob G, Cohen AT, Eriksson BI, et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement: a randomised double-blind dose-response study. Thromb Haemost 2010 Jun 29; 104(3): 642–9PubMedCrossRef Raskob G, Cohen AT, Eriksson BI, et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement: a randomised double-blind dose-response study. Thromb Haemost 2010 Jun 29; 104(3): 642–9PubMedCrossRef
58.
Zurück zum Zitat Fuji T, Wang C-J, Fujita S, et al. Edoxaban in patients undergoing total hip arthroplasty: a phase IIb dose-finding study [abstract]. Blood 2009; 114: 2098 Fuji T, Wang C-J, Fujita S, et al. Edoxaban in patients undergoing total hip arthroplasty: a phase IIb dose-finding study [abstract]. Blood 2009; 114: 2098
59.
Zurück zum Zitat Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009 Dec 1; 104(11): 1534–9PubMedCrossRef Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009 Dec 1; 104(11): 1534–9PubMedCrossRef
60.
Zurück zum Zitat Anon. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994 Jul 11; 154 (13): 1449–57 Anon. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994 Jul 11; 154 (13): 1449–57
61.
Zurück zum Zitat Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002 Oct 1; 113(5): 359–64PubMedCrossRef Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002 Oct 1; 113(5): 359–64PubMedCrossRef
62.
Zurück zum Zitat Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 2007 Nov; 28(22): 2803–17PubMedCrossRef Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 2007 Nov; 28(22): 2803–17PubMedCrossRef
63.
Zurück zum Zitat Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003 Sep 11; 349(11): 1019–26PubMedCrossRef Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003 Sep 11; 349(11): 1019–26PubMedCrossRef
64.
Zurück zum Zitat Chung N, Jeon HK, Lien LM, et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost 2011 Mar; 105(3): 535–44PubMedCrossRef Chung N, Jeon HK, Lien LM, et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost 2011 Mar; 105(3): 535–44PubMedCrossRef
65.
Zurück zum Zitat Yasaka M, Inoue H, Kawai Y, et al. Randomized, parallel group, warfarin control, multicenter phase II study evaluating safety of DU-176b in Japanese subjects with non-valvular atrial fibrillation (NVAF) [abstract]. J Thromb Haemost 2009 Jul; 7 Suppl. 2: PP–WE–196 Yasaka M, Inoue H, Kawai Y, et al. Randomized, parallel group, warfarin control, multicenter phase II study evaluating safety of DU-176b in Japanese subjects with non-valvular atrial fibrillation (NVAF) [abstract]. J Thromb Haemost 2009 Jul; 7 Suppl. 2: PP–WE–196
66.
Zurück zum Zitat Koretsune Y, Inoue H, Kawai Y, et al. The oral factor Xa inhibitor DU-176b in Japanese warfarin-naive patients with atrial fibrillation: results of two phase II open-label, dose-escalation studies [abstract]. 58th Annual Scientific Session of the American College of Cardiology; 2009 Mar 29–31; Orlando (FL), 1022-114 Koretsune Y, Inoue H, Kawai Y, et al. The oral factor Xa inhibitor DU-176b in Japanese warfarin-naive patients with atrial fibrillation: results of two phase II open-label, dose-escalation studies [abstract]. 58th Annual Scientific Session of the American College of Cardiology; 2009 Mar 29–31; Orlando (FL), 1022-114
68.
Zurück zum Zitat Eikelboom JW, O’Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010 Mar; 159(3): 348–53 e1PubMedCrossRef Eikelboom JW, O’Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010 Mar; 159(3): 348–53 e1PubMedCrossRef
69.
Zurück zum Zitat Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011 Mar 3; 364(9): 806–17PubMedCrossRef Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011 Mar 3; 364(9): 806–17PubMedCrossRef
70.
Zurück zum Zitat Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010 Dec 23; 363(26): 2499–510PubMedCrossRef Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010 Dec 23; 363(26): 2499–510PubMedCrossRef
71.
Zurück zum Zitat Gibson CM, Mega JL, Burton P, et al. Rationale and design of the anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J 2011 May; 161(5): 815–21PubMedCrossRef Gibson CM, Mega JL, Burton P, et al. Rationale and design of the anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J 2011 May; 161(5): 815–21PubMedCrossRef
73.
Zurück zum Zitat Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009 Dec 10; 361(24): 2342–52PubMedCrossRef Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009 Dec 10; 361(24): 2342–52PubMedCrossRef
74.
Zurück zum Zitat Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood 2008 Sep 15; 112(6): 2242–7PubMedCrossRef Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood 2008 Sep 15; 112(6): 2242–7PubMedCrossRef
75.
Zurück zum Zitat Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010 Mar; 159(3): 331–9PubMedCrossRef Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010 Mar; 159(3): 331–9PubMedCrossRef
76.
Zurück zum Zitat Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010 Dec; 104(6): 1106–15PubMedCrossRef Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010 Dec; 104(6): 1106–15PubMedCrossRef
77.
Zurück zum Zitat Daiichi-Sankyo. Study ID DU176b-D-U305 [data on file] Daiichi-Sankyo. Study ID DU176b-D-U305 [data on file]
78.
Zurück zum Zitat Daiichi Sankyo Inc. Comparative investigation of low molecular weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study) [ClinicalTrials.gov identifier NCT00986154]. US National Institutes of Health, Clinical-Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 13] Daiichi Sankyo Inc. Comparative investigation of low molecular weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study) [ClinicalTrials.gov identifier NCT00986154]. US National Institutes of Health, Clinical-Trials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2011 Jul 13]
79.
Zurück zum Zitat Fuji T, Wang C-J, Fujita S, et al. Edoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial [abstract]. Pathophysiol Haemost Thromb 2010; 37 Suppl. 1: OC297 Fuji T, Wang C-J, Fujita S, et al. Edoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial [abstract]. Pathophysiol Haemost Thromb 2010; 37 Suppl. 1: OC297
80.
Zurück zum Zitat Fujita S, Fuji T, Tachibana S, et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery [abstract]. Pathophysiol Haemost Thromb 2010; 37 Suppl. 1: P366 Fujita S, Fuji T, Tachibana S, et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery [abstract]. Pathophysiol Haemost Thromb 2010; 37 Suppl. 1: P366
81.
Zurück zum Zitat Fuji T, Fujita S, Tachibana S, et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial. ASH Annual Meeting Abstracts 2010 Nov19; 116(21): 3320 Fuji T, Fujita S, Tachibana S, et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial. ASH Annual Meeting Abstracts 2010 Nov19; 116(21): 3320
82.
Zurück zum Zitat Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008 Jun 26; 358(26): 2765–75PubMedCrossRef Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008 Jun 26; 358(26): 2765–75PubMedCrossRef
83.
Zurück zum Zitat Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008 Jul 5; 372(9632): 31–9PubMedCrossRef Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008 Jul 5; 372(9632): 31–9PubMedCrossRef
84.
Zurück zum Zitat Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008 Jun 26; 358(26): 2776–86PubMedCrossRef Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008 Jun 26; 358(26): 2776–86PubMedCrossRef
85.
Zurück zum Zitat Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009 May 16; 373(9676): 1673–80PubMedCrossRef Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009 May 16; 373(9676): 1673–80PubMedCrossRef
86.
Zurück zum Zitat Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007 Sep 15; 370(9591): 949–56PubMedCrossRef Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007 Sep 15; 370(9591): 949–56PubMedCrossRef
Metadaten
Titel
Edoxaban
A New Oral Direct Factor Xa Inhibitor
verfasst von
Prof. A. John Camm
Henri Bounameaux
Publikationsdatum
01.08.2011
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 12/2011
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/11595540-000000000-00000

Weitere Artikel der Ausgabe 12/2011

Drugs 12/2011 Zur Ausgabe

Therapy in Practice

Acute Myeloid Leukaemia